CASI Pharmaceuticals Inc

NASDAQ:CASIUnited States

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Contact Information

Headquarters

9620 Medical Center Drive, Suite 300BEIJING, BEJ, China 100025

Phone

106-561-8789

Fax

301-315-2437

Executives

Chairman of the Board, Chief Executive Officer

Wei-Wu He

President, Principal Financial Officer

Wei Zhang

Chief Operating Officer

Chunhua Wang

Global Chief Commercial Officer, Executive Vice President, General Manager of Casi China

Huang Hai

Executive Vice President, Chief Medical Officer

Alexander Zukiwski